

Novartis - Recall of Sandimmune® (cyclosporine) oral solution

On September 11, 2023, <u>Novartis announced</u> a consumer level recall of one lot of <u>Sandimmune</u> (<u>cyclosporine</u>) oral solution because of crystal formation observed in some bottles, which could potentially result in incorrect dosing. No other Sandimmune formulations are impacted.

Product Description	NDC Number	Lot Number (Exp Date)
Sandimmune (cyclosporine) oral solution 100 mg/mL, 50 mL bottle	0078-0110-22	FX001691 (12/2025)

- Sandimmune is indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants.
- Crystallization of cyclosporine in Sandimmune oral solution is likely to result in non-uniform
 distribution of the cyclosporine in the product, resulting in under-dosing or over-dosing. There is a
 reasonable probability that under-dosing may result in lower exposures and decrease in efficacy
 which could ultimately lead to graft rejection and graft loss in transplant patients.
- Furthermore, over-dosage may manifest itself as cyclosporine toxicity in the long term if over exposure continues.
- To date, Novartis has not received any reports of adverse events related to this recall.
- Anyone with the affected lot on hand should stop distribution and return product. Patients that
 have bottles from the recalled lot of Sandimmune oral solution should contact their healthcare
 provider.
- Contact Novartis at 1-888-669-6682 for questions regarding this recall.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.